levodopa has been researched along with Anterior Horn Cell Disease in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Chung, SJ; Kim, J; Kim, JS; Kim, KK; Lee, CS; Lim, YM; Park, HK | 1 |
| Gawel, D; Gawel, M; Jamrozik, Z; Kaminska, A; Rowińska-Marcińska, K; Slawek, J; Szmidt-Salkowska, E | 1 |
| Berciano, J; Combarros, O; Corral, J; Infante, J; Pascual, J; Polo, JM; Volpini, V | 1 |
| Müller, T; Russ, H | 1 |
| Hideyama, T; Kwak, S; Momose, T; Shimizu, J; Tsuji, S | 1 |
| Dihenia, B; Krendel, DA; Qureshi, AI; Schneider, JA; Wilmot, G | 1 |
1 review(s) available for levodopa and Anterior Horn Cell Disease
| Article | Year |
|---|---|
Levodopa, motor fluctuations and dyskinesia in Parkinson's disease.
Topics: Animals; Disease Progression; Dyskinesias; Humans; Levodopa; Motor Neuron Disease; Parkinson Disease; Risk Factors | 2006 |
6 other study(ies) available for levodopa and Anterior Horn Cell Disease
| Article | Year |
|---|---|
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome.
Topics: Aged; Aged, 80 and over; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Neuron Disease; Parkinsonian Disorders; Positron-Emission Tomography; Tremor; Tropanes | 2013 |
Electrophysiological features of lower motor neuron involvement in progressive supranuclear palsy.
Topics: Action Potentials; Aged; Aging; Antiparkinson Agents; Electrodiagnosis; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Neuron Disease; Motor Neurons; Muscle, Skeletal; Neural Conduction; Peripheral Nerves; Supranuclear Palsy, Progressive | 2013 |
Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease.
Topics: Alleles; Antiparkinson Agents; Atrophy; Brain Stem; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Neuron Disease; Parkinsonian Disorders; Pedigree; Phenotype; Spinocerebellar Ataxias | 2004 |
A positron emission tomography study on the role of nigral lesions in parkinsonism in patients with amyotrophic lateral sclerosis.
Topics: Aged; Amyotrophic Lateral Sclerosis; Cerebrovascular Circulation; Female; Humans; Levodopa; Male; Middle Aged; Motor Neuron Disease; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Spiperone; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2006 |
Motor neuron disease with parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Fatal Outcome; Female; Humans; Levodopa; Male; Medical Records; Middle Aged; Motor Neuron Disease; Parkinson Disease | 1996 |